【摘要】 我院自1988年4月至1989年9月,用超分割放疗交替化疗治疗中晚其食管癌51例(Ⅰ组):超分割放疗每日2次,每次1.15Gy～1.25Gy,二次间隔≥6小时,每周照射5天,总量为69Gy～75Gy,分二疗程完成。化疗采用DDP20mg+5-Fu 500mg静滴3～5天,分别在放疗前和间隔期用。和常规放疗食管癌(Ⅱ组)回顾性比较,Ⅰ组完全缓解率显著高于Ⅱ组,且1、2年局部控制率以Ⅰ组为高。1、2、3年生存率分析,1年生存率Ⅰ组明显高于Ⅱ组。二组早、后期副作用无显著差别。初步认为,采用超分割放疗交替化疗能提高1年生存率,降低1、2年局部复发率,而不增加后期正常组织反应,明确结论尚待进一步研究。更多还原

【Abstract】 From 1988 to 1989, 51 patients with esophageal carcinoma were treated by AHRC. These patients were irradiated by 1. 15-1. 25 Gy per fraction, twice daily with ≥ 6 hours apart to a total dose of 69-75 Gy/60 F/9 wk. The radiotherapy was split at the middle of the course for two weeks. The chemotherapy consisting of DDP (20mg/m2/d) plus 5-Fu (500mg/m2/d) for 3-5 days, was given prior to and during the split of radiotherapy. Another historial group of 51 patients were taken as control. They were treated from 1986 to 1987 by the conventional radiation to a total dose of 65-70 Gy/35-40 F/7-8wk. The results showed that the CR rate of AHRC was higher than the control (78. 4% VS 60. 8%, P<0. 05). The 1- and 2- year local control rates were 82. 3%, 62. 2% and 61. 1%, 35. 7%, respectively (P<0. 05). 1- year survival rates were 80. 3%, and 61. 8% (P<0. 05). However, the 3- year local control and 2. 5- year survival rates were comparable. AHRC gave more severe bat tolerable acute side-effects. The validity ofAHRC needs further study.更多还原